Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Seasonal Influenza Vaccine Supply for the U.S. 2016-2017 Influenza Season

How much influenza vaccine is projected to be available for the 2016-17 influenza season?

Flu vaccine is produced by private manufacturers, so supply depends on manufacturers. Vaccine manufacturers originally projected that as many as 157 million to 168 million doses of injectable flu vaccine (i.e., inactivated and recombinant flu vaccines) would be made available for the 2016-2017 season.

How much thimerosal-free influenza vaccine is expected to be available for the 2016-17 season?

For the 2016-17 season, manufacturers will produce influenza vaccines containing thimerosal and some vaccines that do not contain thimerosal.

Approximately 120 million doses of thimerosal-free or preservative-free influenza vaccine will be produced for the 2016-2017 flu season

Can I still buy influenza vaccine for the 2016-17 season?

Influenza vaccine pre-booking typically occurs between January and March, though most preparations of vaccine should still be available for purchase. Providers should contact distributors and local vendors about remaining supply. Information about manufacturers and distributors who still have influenza vaccine available for sale can be found at http://www.preventinfluenza.org/ivats/

What can we anticipate in terms of the timing of vaccine availability for the 2016-17 season?

The timing of vaccine availability depends on when production is completed. Some influenza vaccine shipments have already begun and will continue throughout September, October, and November until all of the vaccine is distributed.

Are all influenza vaccines the same?

Different influenza vaccine preparations have different indications as licensed by the FDA. See the table below for an overview of these indications.

Special Consideration Regarding Egg Allergy

The recommendations for vaccination of people with egg allergies have changed for 2016-2017.

People with egg allergies can receive any licensed, recommended age-appropriate influenza vaccine and no longer have to be monitored for 30 minutes after receiving the vaccine. People who have severe egg allergies should be vaccinated in a medical setting and be supervised by a health care provider who is able to recognize and manage severe allergic conditions.

Where can I find information about vaccine supply?

Information about vaccine supply is available on the CDC influenza web site.

 Top of Page

TABLE 1. Influenza vaccines — United States, 2016–17 influenza season

Print-friendly version PDF [128KB, 1 page]

Trade name

Manufacturer

Presentation

Age indication

Mercury (from thimerosal)
µg/0.5 mL

Latex

Route

Inactivated influenza vaccine, quadrivalent (IIV4), standard dose

Fluarix Quadrivalent

GlaxoSmithKline

0.5 mL single-dose prefilled syringe

≥3 yrs

NR

No

IM§

Flulaval Quadrivalent ID Biomedical Corp. of Quebec (distributed by GlaxoSmithKline) 0.5 mL single-dose prefilled syringe ≥6 mos NR No IM

 

 

5.0 mL multi-dose vial

≥6 mos

<25

No

IM

Fluzone Quadrivalent

Sanofi Pasteur

0.25 mL single-dose prefilled syringe

6–35 mos

NR

No

IM

0.5 mL single-dose prefilled syringe

≥36 mos

NR

No

IM

0.5 mL single-dose vial

≥36 mos

NR

No

IM

5.0 mL multidose vial

≥6 mos

25

No

IM

Fluzone Intradermal
Quadrivalent

Sanofi Pasteur

0.1 mL single-dose prefilled microinjection system

18 through 64 yrs

NR

No

ID**

Afluria Quadrivalent

Seqirus

0.5 mL single-dose prefilled syringe

≥18 yrs††

NR

No

IM

 

 

5.0 mL multi-dose vial

≥18 yrs††
(needle and syringe)
18 through 64 years
(jet injector)

24.5

No

IM

Inactivated influenza vaccine, quadrivalent, cell culture-based (ccIIV4), standard dose
Flucelvax Quadrivalent Seqirus 0.5 mL single-dose prefilled syringe ≥4 yrs NR No IM
Inactivated Influenza Vaccine, trivalent (IIV3), standard dose

Afluria

Seqirus

0.5 mL single-dose prefilled syringe

≥9 yrs††

NR

No

IM

5.0 mL multi-dose vial

≥9 yrs††
(needle and syringe)
18 through 64 years
(jet injector)

24.5

No

IM

Fluvirin

Seqirus

0.5 mL single-dose prefilled syringe

≥4 yrs

≤1

Yes§§

IM

5.0 mL multi-dose vial

≥4 yrs

25

No

IM

Adjuvanted Inactivated Influenza Vaccine, trivalent (aIIV3), standard dose

Fluad

Seqirus

0.5 mL single-dose prefilled syringe

≥65 yrs

NR

Yes§§

IM

Inactivated Influenza Vaccine, trivalent (IIV3), High Dose¶¶

Fluzone High-Dose

Sanofi Pasteur

0.5 mL single-dose prefilled syringe

≥65 yrs

NR

No

IM

Recombinant Influenza Vaccine, trivalent (RIV3)***

Flublok

Protein Sciences

0.5 mL single-dose vial

≥18 yrs

NR

No

IM

Live Attenuated Influenza Vaccine, quadrivalent (LAIV4)†††

FluMist Quadrivalent

MedImmune

0.2 mL single-dose prefilled
intranasal sprayer

2 through 49 yrs

NR

No

NAS

Abbreviations: ACIP = Advisory Committee on Immunization Practices; ID = intradermal; IM = intramuscular; NAS = intranasal; NR = not relevant (does not contain thimerosal).
*Immunization providers should check Food and Drug Administration–approved prescribing information for 2016–17 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm . Availability of specific products and presentations might change and differ from what is described in this table.
Standard dose intramuscular IIVs contain 15 µg of each vaccine HA antigen (45 µg total for trivalents and 60 µg total for quadrivalents) per 0.5mL dose.
§For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration may be found in the ACIP General Recommendations on Immunization, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
Quadrivalent inactivated influenza vaccine, intradermal: a 0.1-mL dose contains 9 µg of each vaccine HA antigen (36μg total).
**The preferred injection site is over the deltoid muscle. Fluzone Intradermal Quadrivalent is administered using the delivery system included with the vaccine.
††Age indication per package insert is ≥5 years; however, ACIP recommends that Afluria not be used in children aged 6 months through 8 years because of increased risk for febrile reactions noted in this age group with Seqirus’ 2010 Southern Hemisphere IIV3. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9 years. Afluria is licensed for administration by jet injector for persons aged 18 through 64 years only.
§§Syringe tip cap might contain natural rubber latex.
¶¶High-dose IIV3 contains 60 μg of each vaccine antigen (180 μg total) per 0.5mL dose.
***RIV3 contains 45 μg of each vaccine HA antigen (135 μg total) per 0.5mL dose.
†††ACIP recommends that Flumist (LAIV4) not be used during the 2016–17 season.

TABLE 2. Contraindications and precautions to the use of influenza vaccines — United States, 2016–17 influenza season*

Print-friendly version PDF[119KB, 1 page]

Vaccine

Contraindications

Precautions

IIV

History of severe allergic reaction to any component of the vaccine or after previous dose of any influenza vaccine

Moderate to severe illness with or without fever
History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine

RIV History of severe allergic reaction to any component of the vaccine Moderate to severe illness with or without fever
History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine

LAIV

For the 2016–17 season, ACIP recommends that LAIV not be used. Content below is provided for information.

  History of severe allergic reaction to any component of the vaccine† or after a previous dose of any influenza vaccine
Concomitant aspirin or salicylate-containing therapy in children and adolescents
Children aged 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a health care provider has told them during the preceding 12 months that their child had wheezing or asthma or whose medical record indicates a wheezing episode has occurred during the preceding 12 months
Children and adults who have immunosuppression (including immunosuppression caused by medications or by HIV)
Close contacts and caregivers of severely immunosuppressed persons who require a protected environment
Pregnancy
Receipt of influenza antiviral medication within the previous 48 hours
Moderate to severe illness with or without fever
History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine
Asthma in persons aged ≥5 years
Other underlying medical conditions that might predispose to complications after wild-type influenza infection (e.g., chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)

Abbreviations: ACIP = Advisory Committee on Immunization Practices; IIV = Inactivated Influenza Vaccine; LAIV = Live-Attenuated Influenza Vaccine; RIV = Recombinant Influenza Vaccine.
* Immunization providers should check Food and Drug Administration–approved prescribing information for 2016–17 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, and precautions. Package inserts for US-licensed vaccines are available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm .
History of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of IIV and LAIV. However, ACIP recommends that any licensed, recommended, and appropriate IIV or RIV may be administered to persons with egg allergy of any severity (see Influenza Vaccination of Persons with a History of Egg Allergy).

Top